RT Journal Article
SR Electronic
T1 Anti-inflammatory effects of systemic anti-tumour necrosis factor α treatment in human/murine SCID arthritis
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 428
OP 434
DO 10.1136/ard.58.7.428
VO 58
IS 7
A1 Hiltrud Schädlich
A1 Jörg Ermann
A1 Maria Biskop
A1 Werner Falk
A1 Frauke Sperling
A1 Astrid Jüngel
A1 Jörg Lehmann
A1 Frank Emmrich
A1 Ulrich Sack
YR 1999
UL http://ard.bmj.com/content/58/7/428.abstract
AB OBJECTIVES To evaluate in vivo the contribution of tumour necrosis factor α (TNFα) to the chimeric transfer model of human rheumatoid arthritis synovial membrane into SCID mice (hu/mu SCID arthritis), systemic anti-TNFα treatment was performed and the clinical, serological, and histopathological effects of this treatment assessed.METHODS Animals were treated with the rat-antimouse TNFα monoclonal antibody V1q, starting on day 1 after hu/mu engraftment, twice weekly for 12 weeks. Joint swelling, serum concentrations of human and murine interleukin 6 (IL6), and serum amyloid P (SAP) were measured. Histopathological and immunohistochemical analyses of the joints were also performed at the end of treatment.RESULTS Neutralisation of murine TNFα induced the following effects: (a) reduction of extent and duration of the acute arthritis phase, with significant reduction of joint swelling at two weeks; (b) decrease of murine SAP concentrations after the first antibody administration; and (c) increase of murine IL6 in the serum. At the end of treatment, there was a significant reduction of the inflammatory infiltration in the engrafted joints. Because of the mild degree of joint erosion, no treatment effects could be demonstrated on the destructive process.CONCLUSION In the lymphocyte independent hu/mu SCID arthritis, anti-TNFα treatment reduces local and systemic signs of inflammation.